Gene · 1024
Papers2,191
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 2,191
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Acetylation and Phosphorylation in the Regulation of Hypoxia-Inducible Factor Activities: Additional Options to Modulate Adaptations to Changes in Oxygen Levels. | Life (Basel) | 2023 | 38276269 | PubTator, text mining | PubMed |
| Modulators of MAPK pathway activity during filamentous growth in Saccharomyces cerevisiae. | bioRxiv | 2023 | 38187743 | PubTator, text mining | PubMed |
| H19: An Oncogenic Long Non-coding RNA in Colorectal Cancer. | Yale J Biol Med | 2023 | 38161577 | PubTator, text mining | PubMed |
| Combined Treatment with Host-Directed and Anticytomegaloviral Kinase Inhibitors: Mechanisms, Synergisms and Drug Resistance Barriers. | Pharmaceutics | 2023 | 38140021 | PubTator, text mining | PubMed |
| Comparative Assessment and High-Throughput Drug-Combination Profiling of TEAD-Palmitoylation Inhibitors in Hippo Pathway Deficient Mesothelioma. | Pharmaceuticals (Basel) | 2023 | 38139762 | PubTator, text mining | PubMed |
| Trans-Regulation of Alternative PD-L1 mRNA Processing by CDK12 in Non-Small-Cell Lung Cancer Cells. | Cells | 2023 | 38132164 | PubTator, text mining | PubMed |
| Novel pathogenic variant in MED12 causing non-syndromic dilated cardiomyopathy. | BMC Med Genomics | 2023 | 38129817 | PubTator, text mining | PubMed |
| Development of adaptive anoikis resistance promotes metastasis that can be overcome by CDK8/19 Mediator kinase inhibition. | bioRxiv | 2023 | 38106208 | PubTator, text mining | PubMed |
| Distinct states of nucleolar stress induced by anticancer drugs. | Elife | 2023 | 38099650 | PubTator, text mining | PubMed |
| The Potential of Natural Compounds Regulating Autophagy in the Treatment of Osteoporosis. | J Inflamm Res | 2023 | 38088943 | PubTator, text mining | PubMed |
| Pllans-II: Unveiling the Action Mechanism of a Promising Chemotherapeutic Agent Targeting Cervical Cancer Cell Adhesion and Survival Pathways. | Cells | 2023 | 38067143 | PubTator, text mining | PubMed |
The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super-enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic ductal adenocarcinoma: A hypothesis-generating study. | Clin Transl Med | 2023 | 38037549 | PubTator, text mining | PubMed |
| Unveiling the noncanonical activation mechanism of CDKs: insights from recent structural studies. | Front Mol Biosci | 2023 | 38028546 | PubTator, text mining | PubMed |
| Comprehensive genomic profiling reveals prognostic signatures and insights into the molecular landscape of colorectal cancer. | Front Oncol | 2023 | 38023196 | PubTator, text mining | PubMed |
| Microglia Depletion Reduces Human Neuronal APOE4-Driven Pathologies in a Chimeric Alzheimer's Disease Model. | bioRxiv | 2023 | 38014339 | PubTator, text mining | PubMed |
| Ellagic Acid and Cancer Hallmarks: Insights from Experimental Evidence. | Biomolecules | 2023 | 38002335 | PubTator, text mining | PubMed |
| The Role of Exosome-Derived microRNA on Lung Cancer Metastasis Progression. | Biomolecules | 2023 | 38002256 | PubTator, text mining | PubMed |
| Dpep Inhibits Cancer Cell Growth and Survival via Shared and Context-Dependent Transcriptome Perturbations. | Cancers (Basel) | 2023 | 38001578 | PubTator, text mining | PubMed |
| Inhibition of UFM1 expression suppresses cancer progression and is linked to the dismal prognosis and immune infiltration in oral squamous cell carcinoma. | Aging (Albany NY) | 2023 | 37980168 | PubTator, text mining | PubMed |
| Strategic Approach to Heterogeneity Analysis of Cutaneous Adnexal Carcinomas Using Computational Pathology and Genomics. | JID Innov | 2023 | 37965425 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1024/papers?page=9